You searched for side effects - Page 28 of 311 - Medivizor
Navigation Menu

Which sequence of treatment should be given first- immunotherapy or targeted therapy for patients with BRAF-mutated metastatic melanoma?

Which sequence of treatment should be given first- immunotherapy or targeted therapy for patients with BRAF-mutated metastatic melanoma?

Posted by on Mar 26, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated which sequence of treatment should be given first – immunotherapy or targeted therapy – for the most clinical benefit in patients with BRAF-mutated metastatic melanoma. The data showed that immunotherapy followed by targeted therapy significantly improved survival outcomes in these patients. Some background...

Read More

Evaluating the effectiveness and safety outcomes of atezolizumab given before surgery in patients with non-small cell lung cancer.

Evaluating the effectiveness and safety outcomes of atezolizumab given before surgery in patients with non-small cell lung cancer.

Posted by on Mar 26, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of atezolizumab (Tecentriq) given before surgery for the treatment of patients with non-small cell lung cancer (NSCLC). The data showed that atezolizumab given before surgery was safe and effective for patients with NSCLC. Some background Non-small cell lung cancer (NSCLC)...

Read More

Evaluating the effectiveness and safety of busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for patients with adult B-cell acute lymphoblastic leukemia.

Evaluating the effectiveness and safety of busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for patients with adult B-cell acute lymphoblastic leukemia.

Posted by on Mar 26, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of busulfan (Bu; Busulfex) plus cyclophosphamide (Cy; Cytoxan) (BuCy) regimen versus total body irradiation (TBI) plus cyclophosphamide (TBI-Cy) regimen for patients with adult B-cell acute lymphoblastic leukemia (B-ALL) in first complete remission undergoing allogeneic hematopoietic...

Read More

Evaluating the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer.

Evaluating the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer.

Posted by on Mar 24, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer. The data showed that most patients with breast and gynecological cancer developed antibodies after the second dose of the vaccine. However, the authors suggested that for non-responders or weak...

Read More

Evaluating the effectiveness and safety of oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer.

Evaluating the effectiveness and safety of oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer.

Posted by on Mar 24, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of oral paclitaxel (Taxol) plus encequidar (HM 30181) versus intravenous (IV) paclitaxel in patients with metastatic breast cancer (BC). This study concluded that oral paclitaxel plus encequidar was more effective than IV paclitaxel with manageable side effects in these...

Read More

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Posted by on Mar 5, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of cemiplimab (Libtayo) plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that cemiplimab plus chemotherapy as first-line treatment was effective with manageable side effects in these patients. Some...

Read More

Benefits of combination treatment for diabetic peripheral neuropathic pain.

Benefits of combination treatment for diabetic peripheral neuropathic pain.

Posted by on Mar 5, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the effectiveness and safety of combinations of anti-depressive medication for the treatment of diabetic peripheral neuropathic pain (DPNP) in patients with diabetes. The study showed that combination treatment improved pain in these patients and was well tolerated.  Some background DPNP occurs in patients...

Read More

Combining a “herbal” and conventional disease-modifying anti-rheumatic drug for treating rheumatoid arthritis.

Combining a “herbal” and conventional disease-modifying anti-rheumatic drug for treating rheumatoid arthritis.

Posted by on Mar 5, 2023 in Rheumatoid Arthritis | 0 comments

In a nutshell This study explored the effectiveness and safety of tripterygium glycosides (TG) as a disease-modifying anti-rheumatic drug (DMARD) when combined with conventional DMARDs for treating rheumatoid arthritis (RA). The authors concluded that good safety and better improvements in RA symptoms were observed when TG was combined with a...

Read More

Evaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Evaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Posted by on Mar 5, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of rezvilutamide (Ariane) versus bicalutamide (Casodex) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that rezvilutamide in combination with ADT significantly improved the...

Read More

Evaluating the effectiveness and safety of immune checkpoint inhibitors either alone or in combination for the treatment of advanced malignant melanoma.

Evaluating the effectiveness and safety of immune checkpoint inhibitors either alone or in combination for the treatment of advanced malignant melanoma.

Posted by on Mar 5, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) either alone or in combination for the treatment of patients with advanced melanoma. The data showed that nivolumab (Opdivo) and ipilimumab (Yervoy) combination therapy was more effective than nivolumab or ipilimumab alone for the treatment of...

Read More

Comparing the effectiveness of vaginal laser therapy and hyaluronic acid suppositories in women with urogenital atrophy after breast cancer treatment

Comparing the effectiveness of vaginal laser therapy and hyaluronic acid suppositories in women with urogenital atrophy after breast cancer treatment

Posted by on Mar 5, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the effectiveness of vaginal laser therapy (VL) and hyaluronic acid suppositories (HAS) in women with urogenital atrophy after having breast cancer (BC) treatment. The data found that both VA therapy and HAS were equally effective in treating urogenital atrophy in these patients. Some background Many women...

Read More

Evaluating the risk of cardiovascular disease mortality among long-term survivors of classical Hodgkin lymphoma.

Evaluating the risk of cardiovascular disease mortality among long-term survivors of classical Hodgkin lymphoma.

Posted by on Feb 28, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the risk of cardiovascular disease mortality among long-term survivors of classical Hodgkin lymphoma (cHL). The data showed that patients with early-stage HL are at a higher risk of mortality from cardiovascular disease than from cancer. Some background cHL is a cancer that starts in white blood cells called...

Read More